{"url_path":"/sec/curx/10-q/2026/item-2","section_key":"item-2","section_title":"Item 2 Unregistered Sales Of Equity Securities And Use Of Proceeds**","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-14","source_url":"https://www.sec.gov/Archives/edgar/data/2025942/0001493152-26-022892-index.html","accession_number":"0001493152-26-022892","cik":"0002025942","ticker":"CURX","issuer_name":"Curanex Pharmaceuticals Inc","edgar_url":"https://www.sec.gov/Archives/edgar/data/2025942/0001493152-26-022892-index.html","primary_entity_key":"0002025942","primary_entity_name":"Curanex Pharmaceuticals Inc"},"word_count":122,"has_tables":true,"body_markdown":"**Item\n2. Unregistered Sales Of Equity Securities And Use Of Proceeds**\n\n \n\nExcept\nas stated below, there were no sales of equity securities during the period covered by this Quarterly Report that were not registered\nunder the Securities Act and were not previously reported in a Current Report on Form 8-K filed by the Company.\n\nOn\nMarch 18, 2026, we issued 24,000 shares of Common Stock to our Chief Scientific Officer and director as compensation for services provided\nto the Company.\n\nThe\nabove issuance did not involve any underwriters, underwriting discounts or commissions or any public offering and we believe is exempt\nfrom the registration requirements of the Securities Act by virtue of Section 4(2) thereof as transactions not involving a public offering."}